Skip to main content
Saniona logo

Saniona — Investor Relations & Filings

Ticker · SANION ISIN · SE0005794617 LEI · 549300XO4L9XNOCFCZ84 ST Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2024-10-23 Share Issue/Capital Cha…
Country SE Sweden
Listing ST SANION

About Saniona

http://saniona.com

Saniona is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurological disorders, with a primary emphasis on epilepsy. The company is a leader in the field of ion channel modulation, leveraging its expertise and a proprietary drug discovery engine to create new medicines. Saniona has developed an extensive library of over 20,000 proprietary molecules designed to target various ion channels. Its pipeline includes multiple potential new medicines advancing through clinical trials, with the goal of addressing unmet medical needs for patients with central nervous system diseases.

Recent filings

Filing Released Lang Actions
Fenja Capital II A/S påkallar konvertering av utestående konvertibler med ett totalt nominellt belopp om 2 MSEK
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the conversion of convertible bonds into new shares by Fenja Capital II A/S. This results in an increase in the total number of shares and share capital for Saniona AB. According to the filing definitions, announcements regarding new share issues or capital changes (including conversions of debt to equity) fall under the 'Share Issue/Capital Change' (SHA) category.
2024-10-23 Swedish
Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone
Regulatory Filings Classification · 95% confidence The document is a press release announcing a research milestone payment of €500,000 from a collaboration with Boehringer Ingelheim. It does not constitute a full financial report, proxy statement, or governance document. As it is a corporate announcement regarding business operations and milestone achievements that does not fit into specific categories like M&A or share issues, it is classified as a general regulatory filing (RNS).
2024-10-14 English
Sanionas forskningssamarbete med Boehringer Ingelheim når milstolpe
Regulatory Filings Classification · 95% confidence The document is a press release announcing a milestone payment in a research collaboration between Saniona and Boehringer Ingelheim. It is a short, news-style announcement (under 5,000 characters) that provides details on a specific corporate event. It does not fit into specialized categories like financial reports, proxy statements, or director dealings. As it is a general corporate announcement regarding business operations, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous regulatory disclosures.
2024-10-14 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding (Nordnet AB's stake in Saniona AB) crossing a 5% threshold. This type of disclosure regarding significant changes in share ownership is classified as a Major Shareholding Notification.
2024-10-03 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for Saniona AB, covering the period 'Januari-juni 2024' (January-June 2024). It contains detailed financial tables (Q2 and H1 results), a CEO letter, business updates, and pipeline information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-29 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ending June 30, 2024. It contains detailed financial statements (revenue, operating profit, net profit, cash equivalents, and EPS for both 3-month and 6-month periods), a letter from the CEO, business highlights, and detailed pipeline analysis. It is not an announcement of a report (RPA) nor a simple regulatory filing (RNS), as it provides substantive financial data and management analysis for an interim period. H1 2024
2024-08-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.